Loading
Loading
Growth Hormone & Secretagogues · 10mg + 10mg
Choose dose
Janoshik-tested · 10 vials per kit
CJC-1295 + Ipamorelin is a research blend studied in preclinical research for synergistic growth hormone axis regulation. CJC-1295 prolongs endogenous growth hormone release signals via DAC binding; Ipamorelin selectively stimulates GH secretion at the pituitary level. Research has examined their mechanistically complementary, dual-pathway approach for studying growth hormone secretion rhythms, feedback regulation, and endocrine synergism.
Blended compound — purity note
Peptide blends are not tested for combined purity as a single compound. However, every component is sourced from the same supplier as our individual peptide products, all of which carry valid Janoshik Analytical COAs. Those certificates apply equally to the same peptides in this blend. View individual COAs →
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
CJC-1295 DAC
GHRH Analog with Drug Affinity Complex
CJC-1295 with DAC is a modified analog of growth hormone-releasing hormone (GHRH/GRF(1-44)), the hypothalamic neuropeptide that stimulates pituitary GH secretion. The DAC (Drug Affinity Complex) modification attaches a maleimido propionic acid group to lysine at position 28, enabling covalent binding to cysteine-34 of circulating albumin. This extends half-life from minutes (endogenous GHRH) to approximately 6-8 days, permitting once-weekly dosing in research protocols.
CJC-1295 DAC acts at GHRH receptors on somatotroph cells of the anterior pituitary to stimulate GH synthesis and release in a pulsatile pattern. The sustained albumin-bound depot maintains GHRH receptor occupancy over days, producing prolonged elevation in both GH and downstream IGF-1 levels. Unlike exogenous GH administration, this stimulates physiological GH release from the pituitary, preserving some feedback regulation.
Research has examined CJC-1295 DAC for GH-axis support in age-related GH decline, body composition research (lean mass preservation, visceral fat reduction), post-operative recovery, and IGF-1 upregulation. It is frequently studied in combination with ghrelin mimetics (Ipamorelin, GHRP-2) as these peptides act on the complementary ghrelin receptor pathway to provide synergistic GH pulse amplification.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
